EP Patent
EP0931788A2 — Metalloprotease inhibitors
Assigned to Pfizer Ltd Great Britain · Expires 1999-07-28 · 27y expired
What this patent protects
Compounds of formula (I): <CHEM> where the substituents are as defined herein, and salts thereof, are matrix metalloprotease inhibitors.
USPTO Abstract
Compounds of formula (I): <CHEM> where the substituents are as defined herein, and salts thereof, are matrix metalloprotease inhibitors.
Drugs covered by this patent
- Lumakras (SOTORASIB) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.